FDA opens consultation on device constituent parts for biosimilars, with user-interface comparison at the centre
The FDA published draft guidance on 3 August 2026 covering container closure systems and device constituent parts for biosimilar and interchangeable biosimilar products. It formalises how user-interface differences from the reference product should be analysed. Comments close on 2 October 2026.
Date of development: 3 August 2026 (Federal Register publication; document on public inspection 31 July 2026) Date of publication: 5 August 2026
Key takeaways
FDA issued draft guidance Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts — Docket FDA-2026-D-4272, published at 91 FR 48880 on 3 August 2026.
The guidance was committed to under the BsUFA III goals letter and is jointly issued by CDER and CBER.
It addresses comparative analysis of the user interface of proposed biosimilar and interchangeable biosimilar combination products against the reference product.
When finalised, FDA intends to update section VIII of the Interchangeability guidance and remove Q.I.4 of the Biosimilar Q&As — consolidating scattered recommendations into one document.
Comments are due by 2 October 2026. The guidance is Level 1 draft and non-binding.
What happened
On 3 August 2026 the Food and Drug Administration published a notice of availability in the Federal Register (91 FR 48880, document 2026-15630) announcing draft guidance for industry entitled Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts. The document was placed on public inspection on 31 July 2026 and the guidance itself carries a July 2026 date. It is issued jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, and is designated Draft Level 1 guidance containing non-binding recommendations.
The guidance was produced to fulfil a commitment FDA made during the reauthorisation of the Biosimilar User Fee Act, recorded in the Biosimilar Biological Product Reauthorization Performance Goals and Procedures for Fiscal Years 2023 Through 2027 (the BsUFA III goals letter), to issue guidance on considerations for developing presentations, container closure systems and device constituent parts for proposed interchangeable biosimilar biological products.
According to the Federal Register notice, the draft guidance does three things. It provides a high-level summary of product-quality recommendations for container closure systems and devices that are currently spread across multiple FDA guidances. It describes considerations for evaluating the user interface of proposed biosimilar and interchangeable biosimilar combination product presentations through comparative analyses, to determine whether potential differences from the reference product warrant collecting additional information. And it explains the challenges that arise when seeking licensure of an interchangeable biosimilar combination product in a different presentation from its reference product, encouraging early discussion with the Agency.
What is new compared with the previous position
Until now, FDA's expectations on delivery devices and container closure systems for biosimilars sat in two places: Q.I.4 of Questions and Answers on Biosimilar Development and the BPCI Act (issued 20 September 2021, 86 FR 52154), and section VIII of Considerations in Demonstrating Interchangeability With a Reference Product (issued 14 May 2019, 84 FR 21342).
The Federal Register notice is explicit about the consolidation: when this draft guidance is finalised, FDA intends to update section VIII of the Interchangeability guidance and to remove Q.I.4 of the Biosimilar Q&As. Developers who have been working from a Q&A answer and a guidance section written for a different purpose will, on finalisation, have a single dedicated document.
| Topic | Current source | After finalisation |
|---|---|---|
| Delivery device and container closure development, biosimilars | Q.I.4, Questions and Answers on Biosimilar Development and the BPCI Act (86 FR 52154, 20 September 2021) | New dedicated draft guidance (Q.I.4 to be removed) |
| Presentations for proposed interchangeable products | Section VIII, Considerations in Demonstrating Interchangeability With a Reference Product (84 FR 21342, 14 May 2019) | New dedicated draft guidance (section VIII to be updated) |
| Comparative user interface analysis | Dispersed across multiple guidances | Consolidated in new guidance |
| Different presentation from reference product | Limited explicit treatment | Addressed, with early Agency engagement encouraged |
Why this matters in practice
For device organisations, the significant element is the user-interface comparative analysis. Biosimilar combination products are frequently delivered through an autoinjector or prefilled syringe that differs from the reference product's presentation — different needle shield, different activation force, different audible or visual feedback, different label architecture. Each difference is a potential source of use error and a potential obstacle to a demonstration of biosimilarity or interchangeability.
By setting out how those differences should be analysed comparatively, FDA is signalling that device design decisions in a biosimilar programme are regulatory decisions, taken early, not packaging choices settled late. The notice's specific mention of the difficulties in licensing an interchangeable biosimilar combination product in a different presentation from its reference product is a clear steer that presentation divergence carries programme risk.
For European device developers and CDMOs supplying delivery systems into US biosimilar programmes, this is a specification-setting document. Design inputs, human factors validation strategy and comparative use-related risk analysis will all be shaped by what the final guidance says.
Who is affected
Biosimilar and interchangeable biosimilar applicants filing under section 351(k) of the Public Health Service Act
Developers and manufacturers of autoinjectors, pens, prefilled syringes and on-body delivery systems used as device constituent parts
CDMOs and component suppliers, including EU-based suppliers into US programmes
Human factors and usability engineering teams responsible for comparative use-related risk analysis
Combination product regulatory affairs and design assurance functions
Deadlines and effective dates
31 July 2026 — document placed on public inspection
3 August 2026 — Federal Register publication (91 FR 48880)
2 October 2026 — deadline for comments to be considered before FDA begins work on the final version
Comments may be submitted at any time under 21 CFR 10.115(g)(5), but only those received by 2 October 2026 are guaranteed consideration for the final text
No compliance date applies: draft guidance is non-binding and not for implementation
Practical actions to consider
Download and read the draft guidance itself (FDA media reference 193917), not only the Federal Register notice, before forming a position.
Map your current comparative user-interface analysis against what the draft proposes, and identify where your existing human factors package would fall short.
Review programmes where the proposed presentation differs from the reference product. These are the programmes the draft explicitly flags, and the ones where early Agency engagement is now expressly encouraged.
Prepare a comment by 2 October 2026 if the draft would change your development approach. Docket FDA-2026-D-4272 is open on regulations.gov.
Watch for knock-on effects on existing documents. If you rely on Q.I.4 of the Biosimilar Q&As in a submission strategy, note that FDA intends to remove it on finalisation.
Uncertainties and open questions
The guidance is draft and non-binding. FDA states it does not establish rights and is not binding on the Agency or the public, and alternative approaches remain available.
No finalisation date has been announced. FDA will begin work on the final version after the comment period closes.
The Federal Register notice summarises the guidance but does not reproduce it. The substantive detail of the comparative user-interface methodology is in the guidance document itself, which should be read before drawing conclusions about its impact.
FDA has invited comment specifically on costs or cost savings the guidance may generate, referencing Executive Order 14192 — an indication that the economic framing of comments may carry weight.
QLE perspective
We have no basis to take a position on the technical content of a guidance document we have summarised from its Federal Register notice, and we will not manufacture one. What can be said with confidence is structural: FDA is consolidating device-constituent expectations for biosimilars into a single, dedicated document, and it is putting comparative user-interface analysis at the centre of that document.
For European suppliers, the practical read-across is straightforward. The evidence FDA is describing — comparative use-related risk analysis, design justification for divergence from a reference presentation — is generated by the same usability engineering process that IEC 62366-1 already requires for the EU market. Organisations running a single, well-structured human factors programme will find they can serve both. Organisations running separate US and EU workstreams will pay for the same evidence twice.
The 2 October 2026 comment deadline is the actionable item. Draft guidance is the cheapest point at which industry can influence an expectation that will otherwise be applied to every subsequent submission.
Conclusion
Should device teams supplying biosimilar programmes act on this? Yes — by reading the draft and, if it would change their development approach, commenting by 2 October 2026. The document does not create binding obligations, but it consolidates FDA's expectations on container closure systems and device constituent parts into a single reference and makes comparative user-interface analysis explicit. When finalised, it will supersede Q.I.4 of the Biosimilar Q&As and update section VIII of the Interchangeability guidance, which means it will become the document that submissions are written against.
Sources
Federal Register, Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry; Availability, 91 FR 48880, 3 August 2026 — https://www.federalregister.gov/documents/2026/08/03/2026-15630/biosimilar-and-interchangeable-biosimilar-products-considerations-for-container-closure-systems-and
Official PDF (govinfo) — https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15630.pdf
FDA guidance landing page and draft document — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilar-and-interchangeable-biosimilar-products-considerations-container-closure-systems-and
Draft guidance download — https://www.fda.gov/media/193917/download
Docket FDA-2026-D-4272 — https://www.regulations.gov/docket/FDA-2026-D-4272
Author-review note for Radoslav
The draft guidance document itself was not read during research. Everything in this article is sourced from the Federal Register notice (which reproduces FDA's own summary) and the FDA guidance landing page. Please read the guidance PDF before publication and expand the "Why this matters" section with substantive detail if warranted.
The IEC 62366-1 read-across in the QLE perspective is our analysis, not an FDA statement. Confirm you are content to publish it.
Confirm the BsUFA III goals-letter title and years (Fiscal Years 2023 Through 2027) as quoted in the notice.
Confirm relevance to QLE's audience. This story was scored 4/5 for QLE relevance on the basis that QLE advises on drug-device combination products and international market access. If that is not a service line you wish to signal, consider running article 1 alone this week.
The article states no finalisation date has been announced. Re-check before publication in case FDA has since indicated a target.
